GSK has received approval from Japan's MHLW for its application to extend the indication of its RSV vaccine, Arexvy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback